Daunorubicin retention and sensitivity to efflux blockers in human retroviral-associated lymphomas and leukemias (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Daunorubicin retention and sensitivity to efflux blockers in human retroviral-associated lymphomas and leukemias (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A1119 1993. Unique Identifier : AIDSLINE ICDB/93692090
Krishan A; Byrnes J; Samy TS; Wellham L; Sauerteig A; Harrington WJ Jr; Hussein A; Byrne G; Maharaj D; Goodman M; Univ. of Miami Medical Sch., Miami, FL 33101

Abstract: Several recent studies suggest that transfection of oncogenes (Science 253:449, 1992; Br J Cancer 63:237, 1991) can modulate cellular drug resistance and enhance P-glycoprotein expression (Biochem Biophys Res Comm 171:1002, 1990). The present study was undertaken to see if cells from the lymph nodes and peripheral blood of retroviral-associated lymphoma and leukemia patients have rapid drug efflux. Single cell suspensions obtained from peripheral blood, lymph nodes, and tumor biopsies were incubated for 30 min with 3.55 uM daunorubicin with or without efflux blockers (25 uM prochlorperazine, 10 uM verapamil or 20 uM dipyridamole). Extensive heterogeneity in cellular drug content was noted in 14/17 specimens analyzed by laser flow cytometry. Six out of 17 specimens had subpopulations that were sensitive to the efflux blockers, and 5 of these specimens increased cellular daunorubicin retention in the presence of 25 uM prochlorperazine. In contrast, only 1/6 specimens were sensitive to the efflux blocking action of verapamil. These studies suggest that the use of appropriate efflux blockers in retroviral-associated lymphomas and leukemias may contribute to enhanced chemosensitivity.

Keywords: Cell Survival/DRUG EFFECTS Daunorubicin/*PHARMACOKINETICS Dipyridamole/*PHARMACOLOGY Human Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*METABOLISM Lymph Nodes/DRUG EFFECTS/*METABOLISM Metabolic Clearance Rate Prochlorperazine/*PHARMACOLOGY Tumor Cells, Cultured/DRUG EFFECTS/*METABOLISM Verapamil/*PHARMACOLOGY ABSTRACT
930830
M9380836

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .